MindMaze Group Secures USD 125 Million Financing
Summary
MindMaze, a global pioneer in the digital neurotherapeutics market, currently collaborates with approximately ninety healthcare providers and has a product portfolio that has received three FDA clearances and four CE marks across eight clinical indications. MindMaze delivers seamless digital assessments and therapeutics over the full continuum of care in over twenty countries, with thousands of patients suffering from neurological conditions. The financing was provided by AlbaCore Capital Group, one of Europes leading specialist investors focusing on public and private corporate credit markets. Tej Tadi, PhD, MindMaze founder and CEO, stated: "This investment by AlbaCore will allow us to accelerate our proven neuro-rehab platform and advance commercialization of our evidence-based neuro-restorative solutions in stroke, traumatic brain, aging and Parkinson disease. One avenue to pursue will be to partner with pharmaceutical companies to promote brain repair by combining our digital therapeutic neurorestorative approach with emerging drug discovery.”